

| SPONSOR              | INDICATIV       | LOCALIZARE                       | LINIE                                           | MEDICATIE                         | STATUS            |
|----------------------|-----------------|----------------------------------|-------------------------------------------------|-----------------------------------|-------------------|
| Bristol-Myers Squibb | CHECKMATE 9DX   | hepatic                          | linia 1                                         | Nivolumab                         | inrolare deschisa |
| Bristol-Myers Squibb | CHECKMATE 901   | urotelial                        | linia 1 metastatic                              | Nivolumab+Ipilimumab              | inrolare deschisa |
| Bristol-Myers Squibb | CHECKMATE 047   | melanom                          | linia 1 metastatic                              | Nivolumab+Relatlimab              | inrolare deschisa |
| Bristol-Myers Squibb | CHECKMATE 001   | melanom                          | linia 1 metastatic                              | Nivolumab+NKTR-214                | inrolare deschisa |
| Bristol-Myers Squibb | CA209-76K       | melanom                          | linia 1 adjuvanta Std II                        | Nivolumab                         | inrolare deschisa |
| Bristol-Myers Squibb | CA209-73L       | NSCLC                            | Linia 1 Std III                                 | Nivolumab+Ipilimumab              | inrolare deschisa |
| Bristol-Myers Squibb | CA209-8HW       | colon                            | Linia1/2/3 cu instabilitate<br>microsataelitara | Nivolumab+Ipilimumab              | inrolare deschisa |
| GSK                  | TSR33005        | ovar                             | linia 1                                         | TSR-042                           | inrolare deschisa |
| GSK                  | GSK-209229      | Cap si gat                       | linia 1 metastatic                              | Pembrolizumab+Iqos                | inrolare deschisa |
| Eli Lilly            | I3Y-MC-JPCM     | prostata                         | linia 1 metastatic rezistent la<br>castrare     | Abemaciclib                       | inrolare deschisa |
| Eli Lilly            | I3Y-MC-JPBL     | san                              | linia 1 metastatic                              | Fulvestrant_Abemaciclib           | inrolare deschisa |
| MSD                  | MK-7339-002     | basket tumor<br>(HRRm)(HRD)      | Linia 2/3/4                                     | Olaparib                          | inrolare deschisa |
| MSD                  | MK-3475-630     | cutanat cu celula<br>scuamosa    | linia 1                                         | Pembrolizumab                     | inrolare deschisa |
| MSD                  | MK-7339-006     | NSCLC ADK                        | linia 1                                         | Pembrolizumab+chimio+olap<br>arib | inrolare deschisa |
| MSD                  | MK-7339-008     | NSCLC scuamos                    | linia 1                                         | Pembrolizumab+chimio+olap<br>arib | inrolare deschisa |
| MSD                  | MK-7339-007     | basket tumor<br>(HRRm)(HRD)      | Linia 2/3/4/5                                   | Pembrolizuman+olaparib            | inrolare deschisa |
| Roche                | WO39391         | san triplu negativ               | linia 1 adjuvanta                               | Atezolizumab                      | inrolare deschisa |
| Roche                | Cupisco         | punct de plecare<br>neprecizat   | linia 1                                         | Atezolizumab/Cobinetinib          | inrolare deschisa |
| Roche                | CO-41101        | san triplu negativ<br>metastatic | linia 1                                         | Atezolizumab+Ipatasertib          | inrolare deschisa |
| IPSEN                | MM-398-01-03-04 | SCLC                             | linia 2                                         | Irinotecan lipozomal              | inrolare deschisa |
| BEIGENE              | BGB-A317-306    | esofag metastatic                | linia 1                                         | Tislelizumab                      | inrolare deschisa |
| Helsinn              | ANAM-17-21      | NSCLC                            | linia 1/2/3                                     | casexie                           | inrolare deschisa |